GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Carl Zeiss Meditec AG (OTCPK:CZMWY) » Definitions » Debt-to-Equity

Carl Zeiss Meditec AG (Carl Zeiss Meditec AG) Debt-to-Equity : N/A (As of Dec. 2023)


View and export this data going back to 2007. Start your Free Trial

What is Carl Zeiss Meditec AG Debt-to-Equity?

Carl Zeiss Meditec AG's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0 Mil. Carl Zeiss Meditec AG's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0 Mil. Carl Zeiss Meditec AG's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $0 Mil.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Carl Zeiss Meditec AG's Debt-to-Equity or its related term are showing as below:

CZMWY' s Debt-to-Equity Range Over the Past 10 Years
Min: 0   Med: 0.02   Max: 0.11
Current: 0.07

During the past 13 years, the highest Debt-to-Equity Ratio of Carl Zeiss Meditec AG was 0.11. The lowest was 0.00. And the median was 0.02.

CZMWY's Debt-to-Equity is ranked better than
74.26% of 711 companies
in the Medical Devices & Instruments industry
Industry Median: 0.21 vs CZMWY: 0.07

Carl Zeiss Meditec AG Debt-to-Equity Historical Data

The historical data trend for Carl Zeiss Meditec AG's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Carl Zeiss Meditec AG Debt-to-Equity Chart

Carl Zeiss Meditec AG Annual Data
Trend Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
Debt-to-Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.04 0.05 0.07 0.06 0.07

Carl Zeiss Meditec AG Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Debt-to-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only N/A 0.11 N/A 0.07 N/A

Competitive Comparison of Carl Zeiss Meditec AG's Debt-to-Equity

For the Medical Instruments & Supplies subindustry, Carl Zeiss Meditec AG's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Carl Zeiss Meditec AG's Debt-to-Equity Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Carl Zeiss Meditec AG's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Carl Zeiss Meditec AG's Debt-to-Equity falls into.


Carl Zeiss Meditec AG Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Carl Zeiss Meditec AG's Debt to Equity Ratio for the fiscal year that ended in Sep. 2023 is calculated as

Debt to Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(23.283 + 142.882) / 2304.646
=0.07

Carl Zeiss Meditec AG's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(0 + 0) / 0
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Carl Zeiss Meditec AG  (OTCPK:CZMWY) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Carl Zeiss Meditec AG Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Carl Zeiss Meditec AG's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Carl Zeiss Meditec AG (Carl Zeiss Meditec AG) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Carl Zeiss Meditec AG (OTCPK:CZMWY) » Definitions » Debt-to-Equity
Comparable Companies
XTER:1SXP XTER:FIE XTER:GXI FRA:PHH2 ISRG XPAR:EL BDX TSE:7741 XSWX:ALC RMD OCSE:COLO B WST TSE:4543 XSWX:STMN XPAR:DIM BAX HOLX COO TSE:7733 TSE:6869
Traded in Other Exchanges
CZMWF:USA 1AFX:Italy AFXd:UK 0DHC:UK AFX:Germany AFX:Austria
Address
Goschwitzer Strasse 51-52, Jena, TH, DEU, 07745
Website
https://www.zeiss.com
Carl Zeiss Meditec is one of the largest medical technology companies in the world and it operates in two segments: Ophthalmic devices and Microsurgery. OPT, which made up 75% of sales in 2022, includes refractive lasers, surgical ophthalmic devices, equipment for ophthalmic diagnostics, as well as a portfolio of intraocular lenses and disposable medical instruments. With a low-teens share of the market, Zeiss is the second-largest player in the space. MCS is composed of implants, surgical instruments, and visualization devices used during neurosurgery, spine surgery, and otolaryngology surgery. With over 60% market share, Zeiss is the clear leader in the microsurgery space.